CY1116557T1 - PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLI PRODUCTS AS GLYCOKINASE INHIBITORS FOR THE TREATMENT OF DIABETES - Google Patents

PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLI PRODUCTS AS GLYCOKINASE INHIBITORS FOR THE TREATMENT OF DIABETES

Info

Publication number
CY1116557T1
CY1116557T1 CY20121100985T CY121100985T CY1116557T1 CY 1116557 T1 CY1116557 T1 CY 1116557T1 CY 20121100985 T CY20121100985 T CY 20121100985T CY 121100985 T CY121100985 T CY 121100985T CY 1116557 T1 CY1116557 T1 CY 1116557T1
Authority
CY
Cyprus
Prior art keywords
treatment
fasting
thiadiazoli
glycokinase
pyridin
Prior art date
Application number
CY20121100985T
Other languages
Greek (el)
Inventor
Thomas Daniel Aicher
Steven Armen Boyd
Mark Joseph Chicarelli
Kevin Ronald Condroski
Jay Bradford Fell
John P Fischer
Indrani W Gunawardana
Ronald Jay Hinklin
Ajay Singh
Timothy M Turner
Eli M Wallace
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08834504A external-priority patent/EP2209778B1/en
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of CY1116557T1 publication Critical patent/CY1116557T1/en

Links

Landscapes

  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Παρεχόμενες είναι ενώσεις του Τύπου (I): όπου τα R2, R3, R13, L και D2 είναι όπως ορίζεται στην προδιαγραφή, που είναι χρήσιμες στη θεραπεία ή/και την πρόληψη ασθενειών ή διαταραχών που προκαλούνται από ανεπαρκή επίπεδα δραστικότητας γλυκοκινάσης ή που μπορεί να θεραπεύονται με ενεργοποίηση γλυκοκινάσης που συμπεριλαμβάνει, αλλά δεν περιορίζεται σε αυτές, σακχαρώδη διαβήτη, εξασθενημένη ανοχή γλυκόζης, IFG (εξασθενημένη γλυκόζη σε νηστική κατάσταση) και IFG (εξασθενημένη γλυκαιμία σε νηστική κατάσταση), καθώς επίσης άλλες ασθένειες και διαταραχές όπως αυτές που συζητούνται στο παρόν.Provided are compounds of Formula (I): wherein R2, R3, R13, L and D2 are as defined in the specification, useful in the treatment and / or prevention of diseases or disorders caused by inadequate levels of glucokinase activity or which may are treated with, but not limited to, glucokinase activation including diabetes mellitus, impaired glucose tolerance, IFG (fasting glucose in fasting) and IFG (fasting glycemia in fasting), as well as other diseases and disorders such as as those discussed herein.

CY20121100985T 2007-09-21 2012-10-19 PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLI PRODUCTS AS GLYCOKINASE INHIBITORS FOR THE TREATMENT OF DIABETES CY1116557T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97422507A 2007-09-21 2007-09-21
EP08834504A EP2209778B1 (en) 2007-09-21 2008-09-15 Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
CY1116557T1 true CY1116557T1 (en) 2017-03-15

Family

ID=58459743

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100985T CY1116557T1 (en) 2007-09-21 2012-10-19 PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLI PRODUCTS AS GLYCOKINASE INHIBITORS FOR THE TREATMENT OF DIABETES

Country Status (1)

Country Link
CY (1) CY1116557T1 (en)

Similar Documents

Publication Publication Date Title
ECSP078060A (en) 2,4-DIAMINO-PYRIMIDINS AS AURORA INHIBITORS
CR20110077A (en) DIOXA-BICYCLE DERIVATIVES [3.2.1] OCTANO-2,3,4-TRIOL
CR20150131A (en) PIRIDIN-2-IL-AMINO-1,2,4-TIADIAZOL DERIVATIVES AS GLUCOQUINASE ACTIVATORS FOR THE TREATMENT OF MELLITUS DIABETES
BRPI0911035B8 (en) pyrrolidinone glycokinase activators
ECSP056240A (en) PIRIDO DERIVATIVES [2,1-A] ISOQUINOLINE AS DPP-IV INHIBITORS
NO20082096L (en) Azaindole-2-karboksamidderivativer
CY1112429T1 (en) Substituted Sulfonamide Derivatives
NO20072608L (en) Biaryloksymetylarenkarboksylsyrer
BRPI0912923A8 (en) COMPOUND CONSISTING OF A MODIFIED OLIGONUCLEOTIDE COMPOSED OF 12-30 LINKED NUCLEOSIDES, COMPOUNDS COMPRISING ONE MODIFIED OLIGONUCLEOTIDE COMPRISING AT LEAST 12 LINKED NUCLEOSIDES, COMPOUND COMPRISING A MODIFIED OLIGONUCLEOTIDE COMPRISING NUCLEOSIDES ATTACHED SIDES, AND, USE OF A COMPOUND
NO20072389L (en) Substituted benzoquinoline derivatives
EA200701471A1 (en) Substituted pyridinyl and pyrimidinyl derivatives, used as modulators of metabolic disease and treatment of disorders associated with it
NO20055680L (en) Hexahydropyridoisoquinolines as DPP-IV inhibitors
BRPI0407620A (en) Aryl and heteroaryl derivatives substituted as glucose metabolism modulators and prophylaxis and treatment of their disorders
NO20082136L (en) 1,5-substituted indol-2-yl amide derivatives
NO20090173L (en) Condensed spiroketal derivative and its use as a drug for treating diabetes
NO20083058L (en) Cyclohexylsulfonamide derivatives with H3 receptor activity
ATE449776T1 (en) PYRROLOÄ2,3-CÜPYRIDINE DERIVATIVES
MA32723B1 (en) Anilino-pyrimidine derivatives substituted with sulfoximine marked as CDK inhibitors, their preparation and use as drugs
NO20082214L (en) 1,1-Dioxo-thiomorpholinyl-indolyl-methanone derivatives for use as H3 modulators
DK1745010T3 (en) Substituted cyclohexyl-1,4-diamine derivatives
DK1846430T3 (en) Hitherto unknown macrolides
DE602006002612D1 (en) PREPARATION OF (S) -4-FLUOROMETHYL-DIHYDRO-FURAN-2-ON
ATE481395T1 (en) CYCLOHEXYL DERIVATIVES
CY1116557T1 (en) PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLI PRODUCTS AS GLYCOKINASE INHIBITORS FOR THE TREATMENT OF DIABETES
MX2007010841A (en) Substituted, bicyclic 8-pyrrolidino-benzimidazoles, method for their production and their use as medicaments.